This study was designed to determine the technical feasibility, safety, efficacy, and potential to downstage patients to within transplantation criteria when treating patients with hepatocellular carcinoma (HCC) of the caudate lobe using Y90 radioembolization.
During a 4-year period, 8 of 291 patients treated with radioembolization for unresectable HCC had disease involving the caudate lobe. All patients were followed for treatment-related clinical/biochemical toxicities, serum tumor marker response, and treatment response. Imaging response was assessed with the World Health Organization (WHO) and European Association for the Study of the Liver (EASL) classification schemes. Pathologic response was reported as percent necrosis at explantation.
Caudate lobe radioembolization was successfully performed in all eight patients. All patients presented with both cirrhosis and portal hypertension. Half were United Network for Organ Sharing (UNOS) stage T3 (n = 4, 50%). Fatigue was reported in half of the patients (n = 4, 50%). One (13%) grade 3/4 bilirubin toxicity was reported. One patient (13%) showed complete tumor response by WHO criteria, and three patients (38%) showed complete response using EASL guidelines. Serum AFP decreased by more than 50% in most patients (n = 6, 75%). Four patients (50%) were UNOS downstaged from T3 to T2, three of who underwent transplantation. One specimen showed histopathologic evidence of 100% complete necrosis, and two specimens demonstrated greater than 50% necrosis.
Radioembolization with yttrium-90 appears to be a feasible, safe, and effective treatment option for patients with unresectable caudate lobe HCC. It has the potential to downstage patients to transplantation.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
(2004) TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada
Bruix J, Castells A, Bosch J et al (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111(4):1018–1022
Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27(6):1578–1583
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430
Chaib E, Ribeiro MA Jr, de Silva F, Saad WA, Cecconello I (2007) Surgical approach for hepatic caudate lobectomy: review of 401 cases. J Am Coll Surg 204(1):118–127
Hirooka M, Kisaka Y, Uesugi K et al (2009) Virtual puncture line in radiofrequency ablation for hepatocellular carcinoma of the caudate lobe. AJR Am J Roentgenol 193(2):W149–W151
Ibrahim SM, Lewandowski RJ, Sato KT et al (2008) Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 14(11):1664–1669
Ibrahim SM, Nikolaidis P, Miller FH et al (2008) Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 34:572
Kim HC, Chung JW, Jae HJ et al (2010) Caudate lobe hepatocellular carcinoma treated with selective chemoembolization. Radiology 257(1):278–287
Lewandowski RJ, Kulik LM, Riaz A et al (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920–1928
Lewandowski RJ, Mulcahy MF, Kulik LM et al (2010) Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 255(3):955–965
Lewandowski RJ, Sato KT, Atassi B et al (2007) Radioembolization with (90)Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30(4):571–592
Liu DM, Salem R, Bui JT et al (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16(7):911–935
Liu P, Yang JM, Niu WY et al (2010) Prognostic factors in the surgical treatment of caudate lobe hepatocellular carcinoma. World J Gastroenterol 16(9):1123–1128
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214
Riaz A, Lewandowski RJ, Kulik L et al (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol 33:1143–1152
Riaz A, Miller FH, Kulik LM et al (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 303(11):1062–1069
Riaz A, Ryu RK, Kulik LM et al (2009) Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 27(34):5734–5742
Salem R, Lewandowski RJ, Mulcahy MF et al (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52–64
Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278
Seror O, Haddar D, N’Kontchou G et al (2005) Radiofrequency ablation for the treatment of liver tumors in the caudate lobe. J Vasc Interv Radiol 16(7):981–990
Shibata T, Kubo S, Tabuchi T et al (2000) Percutaneous ethanol injection for hepatocellular carcinoma originating in the caudate lobe. Hepatogastroenterology 47(33):824–827
Shibata T, Maetani Y, Ametani F, Kubo T, Itoh K, Konishi J (2002) Efficacy of nonsurgical treatments for hepatocellular carcinoma in the caudate lobe. Cardiovasc Intervent Radiol 25(3):186–192
Takayama T, Makuuchi M (1998) Segmental liver resections, present and future-caudate lobe resection for liver tumors. Hepatogastroenterology 45(19):20–23
Takayasu K, Muramatsu Y, Shima Y et al (1986) Clinical and radiologic features of hepatocellular carcinoma originating in the caudate lobe. Cancer 58(7):1557–1562
Tanaka S, Shimada M, Shirabe K et al (2005) Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe. Am J Surg 190(3):451–455
Terayama N, Miyayama S, Tatsu H et al (1998) Subsegmental transcatheter arterial embolization for hepatocellular carcinoma in the caudate lobe. J Vasc Interv Radiol 9(3):501–508
Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181
Yoon CJ, Chung JW, Cho BH et al (2008) Hepatocellular carcinoma in the caudate lobe of the liver: angiographic analysis of tumor-feeding arteries according to subsegmental location. J Vasc Interv Radiol 19(11):1543–1550 quiz 1550
Conflict of interest
Saad M. Ibrahim, Laura Kulik, Talia Baker, Robert K. Ryu, Mary F. Mulcahy, Michael Abecassis, and Robert J. Lewandowski have no conflicts of interest. Riad Salem is a consultant for MDS Nordion.
About this article
Cite this article
Ibrahim, S.M., Kulik, L., Baker, T. et al. Treating and Downstaging Hepatocellular Carcinoma in the Caudate Lobe with Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol 35, 1094–1101 (2012). https://doi.org/10.1007/s00270-011-0292-x
- Interventional oncology
- Clinical practice
- Hepatocellular carcinoma (HCC)